Lean PMOS: When BMI Doesn't Show the Problem

7 min read · Updated June 1, 2026

The most common opening question we get from women newly investigating PMOS is some version of "my doctor said I can't have PCOS because I'm not overweight." Sometimes that's followed by "...but my periods have been irregular for years" or "...I have facial hair I shouldn't have" or "...we've been trying to conceive for 18 months."

The first sentence is wrong. The second three are exactly the picture of a subtype the clinical literature increasingly calls lean PMOS — PMOS without the body weight that the cliché version of the diagnosis assumes.

This piece is for the women who land here after that conversation with their doctor.

What "lean PMOS" actually means

Polyendocrine Metabolic Ovarian Syndrome (formerly PCOS, renamed in The Lancet, May 2026) is diagnosed by the Rotterdam criteria — meeting at least two of three features: irregular ovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound.

Body weight is not one of the three criteria. It never was. It became culturally associated with PCOS because the metabolic subtype — the one where insulin resistance drives weight gain — is the most visible presentation and the most common reason patients show up at the clinic. But it's not the only presentation.

In current research, lean PMOS is roughly defined as a BMI under 25 (under 23 in Asian populations using WHO Western Pacific cutoffs) with all the other PMOS features intact: androgen excess, ovulatory irregularity, often the ultrasound findings, and — here's the important part — frequently the same underlying insulin signaling problems as women with higher BMIs.

Estimates vary, but credible cohorts put lean PMOS at somewhere between 20% and 30% of all PMOS cases. In Asian populations, the proportion may be higher: a 2024 NUS Medicine study found Singaporean women with PMOS showed a higher proportion of the SHBG-dominant subtype (27% in Singapore vs. 24–34% across other regions), and the SHBG-dominant pattern overlaps significantly with lean presentations.

Why lean PMOS gets missed

Three reasons keep stacking up.

Visual heuristic. A clinician trained on the textbook image of PCOS — overweight, central adiposity, acne, hirsutism — sees a normal-BMI woman in the chair and the pattern-match doesn't trigger. The investigation gets stalled at "let's just see if your cycles regulate on their own" instead of moving to a metabolic workup.

Standard panel blind spots. A typical PCOS / PMOS workup orders total testosterone, LH, FSH, prolactin, TSH, fasting glucose, and a pelvic ultrasound. For lean PMOS, this misses the point. Total testosterone can look normal while SHBG is low (meaning more biologically active free testosterone). Fasting glucose can be in range while fasting insulin is running 15-25 µIU/mL, indicating early insulin resistance that won't show up until glucose breaks. The labs that matter for lean PMOS often have to be specifically requested: SHBG, free testosterone (or calculated free androgen index), fasting insulin, and HOMA-IR.

The "metabolic" framing of PMOS, ironically, makes it worse. The rename to PMOS was meant to bring metabolic health into the center of the diagnosis — a long-overdue correction. But in practice, "metabolic" often gets translated by clinicians as "this only counts if you're overweight." Women with lean phenotypes can hear "your labs are fine" even when their fasting insulin and androgen-to-SHBG ratios are pointing at the same underlying biology that's been quietly running for years.

What this looks like in real terms

A 28-year-old with a BMI of 22, regular but long cycles (35-42 days), chin hair she's been plucking weekly since 19, persistent jawline acne that didn't respond to two rounds of Accutane, and difficulty conceiving for 14 months. Total testosterone: 45 ng/dL (within range). LH/FSH ratio: 2.1 (slightly elevated). Fasting glucose: 88 mg/dL (normal). Her primary care doctor says "everything looks fine; come back if you don't conceive in another 6 months."

What's actually happening: SHBG is 22 nmol/L (low end of range), meaning her free androgen index is sitting at 6.5 — well above the 4.5 threshold typically used to flag biochemical hyperandrogenism. Fasting insulin (not run) would likely be 18-22 µIU/mL, giving a HOMA-IR around 3.5 (above the 2.5 threshold for insulin resistance). She has the full PMOS picture; the standard panel just didn't surface it.

What to ask for

If you suspect lean PMOS and the standard workup has been "normal," these are reasonable next requests at your next clinical visit. The framing matters — these are clinically defensible, not biohacker tests.

• SHBG (sex hormone binding globulin) — required to interpret testosterone meaningfully
• Free testosterone, or calculated free androgen index (FAI) — what your androgen receptors actually see
• Fasting insulin — paired with fasting glucose, used to calculate HOMA-IR
• HbA1c — three-month average glucose, can be elevated before fasting glucose moves
• AMH (anti-Müllerian hormone) — surrogate for follicle count if ultrasound is equivocal
• Lipid panel beyond total cholesterol — HDL particle size, triglycerides, ApoB if available

Most of these are inexpensive and well within standard practice. The conversation is "given the symptom pattern and the rename to PMOS, can we look at SHBG, free testosterone, and fasting insulin?" — not a list of fringe demands.

What lifestyle approaches actually move the needle for lean PMOS

Treatment for lean PMOS doesn't look like treatment for metabolic PMOS. The big-lever interventions are different.

Weight loss is usually not the primary lever because there isn't excess weight to lose. In some cases, modest weight gain (more lean mass, not fat) actually improves outcomes by raising SHBG.

Resistance training is consistently the highest-evidence intervention for lean PMOS. It improves insulin sensitivity at any body weight, raises SHBG over months of consistent training, and addresses the lean mass deficit that can quietly accompany lean PMOS. Two to three sessions per week, progressive load, 12+ weeks before evaluating change.

Protein intake of around 1.6 g/kg lean body mass supports both the training adaptation and blunts the insulin response to mixed meals.

Inositol has the strongest supplement evidence across PMOS subtypes; the magnitude of effect in lean populations is moderate (better than placebo, smaller than in metabolic subtype). Myo-inositol at 2g twice daily is the most-studied protocol.

Spironolactone, combined oral contraceptives, or both are reasonable to discuss with a clinician when androgenic symptoms are the dominant complaint and lifestyle plus inositol haven't moved enough at 6-9 months.

What does not belong in a lean PMOS protocol: aggressive caloric restriction (lowers SHBG further, makes things worse), very-low-carb if not weight-driven, and any GLP-1 agonist as a default (these are studied predominantly in overweight populations; the evidence for lean PMOS is sparse).

Why this matters

The cliché image of PCOS — and the cliché clinical pathway built on it — has been getting it wrong for a meaningful fraction of women for decades. The PMOS rename is a correction at the level of language. Whether it becomes a correction at the level of clinical practice depends on how many women learn what to ask for, and how many clinicians update their default investigation.

If you've been told you can't have PCOS because your BMI is fine, and the symptoms haven't stopped happening, you're not crazy. You're probably looking at a subtype that doesn't show up on a scale.

Where to start

If you want to see what your specific PMOS profile looks like across the four working subtypes, our free 10-minute assessment is calibrated with Asian BMI cutoffs and weights SHBG / androgen markers earlier than most Western-derived protocols do. It's not a diagnosis. It's a structured starting point for the conversation with your clinician.

---

Citations

• Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026 May 12.
• NUS Yong Loo Lin School of Medicine. Studies reveal Asian and Singaporean women with PCOS may experience longer reproductive lifespans and more favourable reproductive outcomes. 2024.
• Dapas M, et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis. PLOS Medicine. 2020.
• Brighten J. PCOS Has a New Name: What PMOS Means and What Still Hasn't Changed. The Dr. Brighten Show, Episode 140. 2026 May 14.

---

This article is for informational purposes only and does not constitute medical advice.